Hematologic Oncology

Parameswaran Hari, MD, reviews challenges in defining the incidence of transplant-associated thrombotic microangiopathy; an expert panel comments on the volume of autologous transplants performed in expert centers.

Jeffrey Laurence, MD, provides an overview of transplant-associated thrombotic microangiopathy (TA-TMA), the associated risk factors, and the role of the complement pathway in TA-TMA development.

Richard M. Stone, MD, discusses the promise of menin inhibitors in patients with acute myeloid leukemia.

Navneet Majhail, MD, MS, discusses the importance of utilizing social media in oncology.

Corey S. Cutler, MD, MPH, FRCPC, discusses the toxicity profile of belumosudil in patients with chronic graft-versus-host disease.

The real-world utilization of axicabtagene ciloleucel demonstrated favorable outcomes and less frequent toxicity events compared with those reported in the pivotal ZUMA-1 trial and other real-world studies.

The trispecific killer cell engager product GTB-3550 was found to result in up to a 63.7% reduction in bone marrow blast levels in patients with high-risk myelodysplastic syndromes and relapsed/refractory acute myeloid leukemia.

The European Commission has approved an expanded label for pembrolizumab for use as a single agent in the treatment of select adult and pediatric patients aged 3 years and older who have relapsed/refractory classical Hodgkin lymphoma.

What to look forward to in the polycythemia vera space, including new clinical trials.

Experts give real-world insight in using ruxolitinib in patients with polycythemia vera. 

Corey S. Cutler, MD, MPH, FRCPC, discusses ​the efficacy results of the ongoing phase 2 ROCKstar trial in patients with chronic graft-versus-host disease.

Sergio A. Giralt, MD, discusses the potential utility of omidubicel in hematologic malignancies.

The MASP-2 inhibitor narsoplimab demonstrated high response rates and a significant improvement in laboratory markers and organ function irrespective of subgroup in adult patients with high-risk hematopoietic stem cell transplant–associated thrombotic microangiopathy.

Lisocabtagene maraleucel was successfully administered in patients with relapsed/refractory aggressive large B-cell lymphoma who were at nonuniversity medical centers in both the outpatient and inpatient settings through the use of standard operating procedures and multidisciplinary teams

Ruxolitinib has demonstrated sustained efficacy with a lower probability of progression or additional systemic therapeutics in patients with steroid-refractory acute graft-versus-host disease.

The engineered cord endothelial cell product AB-205 showed an encouraging safety profile along with robust effects in eliminating oral/gastrointestinal severe regimen-related toxicities in patients with systemic lymphoma undergoing high-dose therapy and autologous hematopoietic stem cell transplantation.

The safety and efficacy of the antibody-drug conjugate camidanlumab tesirine is under investigation in patients with relapsed/refractory Hodgkin lymphoma as part of a phase 2 clinical trial, which recently completed accrual.

Axicabtagene ciloleucel elicited a high objective response rate of 85%, with a complete response rate of 74% when used as a first-line therapy in patients with high-risk large B-cell lymphoma.

A risk-adapted CD19 CAR T-cell therapy dosing approach allowed pediatric patients with relapsed/refractory acute lymphocytic leukemia to maintain a high rate of remission, while reducing the risk of severe toxicities among those with a high initial disease burden

Sergio A. Giralt, MD, discusses the results of a phase 3 trial comparing omidubicel with standard umbilical cord blood transplant in hematologic malignancies.

Omidubicel was associated with a significantly improved median time to neutrophil engraftment compared with standard umbilical cord blood transplantation in patients with high-risk hematologic malignancies.

An overview of the MAGNIFY data and implications for treating appropriate patients with relapsed/refractory follicular lymphoma with the R2 regimen.

Devimistat, a small molecule that targets enzymes involved in cancer cell metabolism, holds promise for older patients with relapsed or refractory acute myeloid leukemia who typically have a poor prognosis with standard-of-care chemotherapy

Corey S. Cutler, MD, MPH, FRCPC; Adam Bagg, MD; Alexander E. Perl, MD, MS; Eunice S. Wang, MD; and Harry P. Erba, MD, PhD, share closing thoughts and emerging therapies on the horizon for the treatment of AML.

Patient selection for maintenance therapy post-allogeneic transplant in myeloid malignancies and thoughts on treatment of FLT3-mutated disease post-transplant with agents such as midostaurin.

Recommendations for treating patients with relapsed/refractory follicular lymphoma with an available PI3K inhibitor and managing adverse events from treatment.

The FDA has extended the review period for the new drug application for belumosudil for use in patients with chronic graft-versus-host disease to allow for more time to review additional data submitted by the biopharmaceutical company.

Paul G. Richardson, MD; Nina Shah, MD; David Siegel, MD, PhD; and Saad Z. Usmani, MD, provide closing thoughts and key takeaways on multiple myeloma from the 2020 ASH Virtual Meeting and future directions for disease management.